Literature DB >> 24872596

Personal utility in genomic testing: is there such a thing?

Eline M Bunnik1, A Cecile J W Janssens2, Maartje H N Schermer1.   

Abstract

In ethical and regulatory discussions on new applications of genomic testing technologies, the notion of 'personal utility' has been mentioned repeatedly. It has been used to justify direct access to commercially offered genomic testing or feedback of individual research results to research or biobank participants. Sometimes research participants or consumers claim a right to genomic information with an appeal to personal utility. As of yet, no systematic account of the umbrella notion of personal utility has been given. This paper offers a definition of personal utility that places it in the middle of the spectrum between clinical utility and personal perceptions of utility, and that acknowledges its normative charge. The paper discusses two perspectives on personal utility, the healthcare perspective and the consumer perspective, and argues that these are too narrow and too wide, respectively. Instead, it proposes a normative definition of personal utility that postulates information and potential use as necessary conditions of utility. This definition entails that perceived utility does not equal personal utility, and that expert judgment may be necessary to help determine whether a genomic test can have personal utility for someone. Two examples of genomic tests are presented to illustrate the discrepancies between perceived utility and our proposed definition of personal utility. The paper concludes that while there is room for the notion of personal utility in the ethical evaluation and regulation of genomic tests, the justificatory role of personal utility is not unlimited. For in the absence of clinical validity and reasonable potential use of information, there is no personal utility. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24872596     DOI: 10.1136/medethics-2013-101887

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  41 in total

Review 1.  Personal utility in genomic testing: a systematic literature review.

Authors:  Jennefer N Kohler; Erin Turbitt; Barbara B Biesecker
Journal:  Eur J Hum Genet       Date:  2017-03-15       Impact factor: 4.246

Review 2.  Ethical issues in pediatric genetic testing and screening.

Authors:  Jeffrey R Botkin
Journal:  Curr Opin Pediatr       Date:  2016-12       Impact factor: 2.856

3.  Defining personal utility in genomics: A Delphi study.

Authors:  J N Kohler; E Turbitt; K L Lewis; B S Wilfond; L Jamal; H L Peay; L G Biesecker; B B Biesecker
Journal:  Clin Genet       Date:  2017-04-19       Impact factor: 4.438

4.  Patients' perceived utility of whole-genome sequencing for their healthcare: findings from the MedSeq project.

Authors:  Philip J Lupo; Jill O Robinson; Pamela M Diamond; Leila Jamal; Heather E Danysh; Jennifer Blumenthal-Barby; Lisa Soleymani Lehmann; Jason L Vassy; Kurt D Christensen; Robert C Green; Amy L McGuire
Journal:  Per Med       Date:  2016-01-08       Impact factor: 2.512

5.  Was it worth it? Patients' perspectives on the perceived value of genomic-based individualized medicine.

Authors:  Colin Me Halverson; Kristin E Clift; Jennifer B McCormick
Journal:  J Community Genet       Date:  2016-02-09

6.  Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project.

Authors:  Stacey Pereira; Jill Oliver Robinson; Amanda M Gutierrez; Devan K Petersen; Rebecca L Hsu; Caroline H Lee; Talia S Schwartz; Ingrid A Holm; Alan H Beggs; Robert C Green; Amy L McGuire
Journal:  Pediatrics       Date:  2019-01       Impact factor: 7.124

7.  Utilization of Genetic Counseling after Direct-to-Consumer Genetic Testing: Findings from the Impact of Personal Genomics (PGen) Study.

Authors:  Diane R Koeller; Wendy R Uhlmann; Deanna Alexis Carere; Robert C Green; J Scott Roberts
Journal:  J Genet Couns       Date:  2017-05-16       Impact factor: 2.537

8.  Understanding What Information Is Valued By Research Participants, And Why.

Authors:  Consuelo H Wilkins; Brandy M Mapes; Rebecca N Jerome; Victoria Villalta-Gil; Jill M Pulley; Paul A Harris
Journal:  Health Aff (Millwood)       Date:  2019-03       Impact factor: 6.301

9.  Parents' Experience with Pediatric Microarray: Transferrable Lessons in the Era of Genomic Counseling.

Authors:  R Z Hayeems; R Babul-Hirji; N Hoang; R Weksberg; C Shuman
Journal:  J Genet Couns       Date:  2015-08-12       Impact factor: 2.537

10.  A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.

Authors:  Ryan W Walker; Gillian M Belbin; Elena P Sorokin; Tielman Van Vleck; Genevieve L Wojcik; Arden Moscati; Christopher R Gignoux; Judy Cho; Noura S Abul-Husn; Girish Nadkarni; Eimear E Kenny; Ruth J F Loos
Journal:  J Hepatol       Date:  2020-03-05       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.